Global & India Cancer Therapeutics Market to 2031

India has experienced a marked increase in cancer cases over recent years, highlighting the urgent need for advanced treatment options. According to GLOBOCAN 2020 data, the country reported approximately 1.3 million new cancer diagnoses. Breast cancer, lung cancer, leukemia, and non-Hodgkin lymphoma are among the most frequently observed types. Specifically, breast cancer accounted for 13.5% (178,361) of all cancer cases and 10.6% (90,408) of cancer-related deaths, with a cumulative risk rate of 2.81.

The growing demand for effective therapies has led to a wave of new product launches in India, particularly targeting breast cancer through genomic techniques, targeted therapies, and immunotherapies. These developments have not only improved treatment outcomes but have also opened up new opportunities for pharmaceutical companies to expand their oncology portfolios. For example, in January 2023, a wholly owned subsidiary of Sun Pharmaceutical Industries Limited launched Palbociclib, a next-generation cancer treatment, for patients with advanced breast cancer—the most commonly diagnosed cancer among Indian women.

In January 2024, AstraZeneca India Pharma Ltd., in collaboration with Daiichi Sankyo, introduced trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate designed for adult patients with unresectable or metastatic HER2-positive breast cancer who have already undergone prior anti-HER2 therapy. Additionally, in November 2024, Dr. Reddy’s Laboratories launched toripalimab, an immuno-oncology drug approved by major regulatory agencies including the USFDA, EMA, and MHRA, for treating adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). These new therapies are playing a crucial role in addressing the treatment gap in India’s cancer care landscape and are contributing significantly to the growth of the cancer therapeutics market in the country.